6,7-dihydro-1,1,2,3,3-pentamethyl-4-(5H)indanone: polycyclic musk fragrance; structure in first source
ID Source | ID |
---|---|
PubMed CID | 92292 |
CHEMBL ID | 3183584 |
SCHEMBL ID | 232766 |
MeSH ID | M0286917 |
Synonym |
---|
1,2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl-4h-inden-4-one |
4h-inden-4-one, 1,2,3,5,6,7-hexahydro-1,1,2,3,3-pentamethyl- |
cashmeran |
6,7-dihydro-1,1,2,3,3-pentamethyl-4(5h)-indanone |
einecs 251-649-3 |
33704-61-9 |
FT-0664402 |
1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one |
dtxsid8047399 , |
tox21_302677 |
NCGC00256636-01 |
dtxcid6027399 |
cas-33704-61-9 |
(+-)-cashmeran |
ec 251-649-3 |
ccris 8406 |
6,7-dihydro-1,1,2,3,3-pentamethyl-4-(5h)indanone |
bzr4438my4 , |
musk indanone |
unii-bzr4438my4 |
dihydro-1,1,2,3,3-pentamethyl-4(5h)-indanone |
(+/-)-cashmeran |
dihydro pentamethylindanone |
4(5h)-indanone, 6,7-dihydro-1,1,2,3,3-pentamethyl- |
dihydro pentamethylindanone [inci] |
SCHEMBL232766 |
1,1,2,3,3-pentamethyl-1,2,3,5,6,7-hexahydro-inden-4-one |
AKOS022171974 |
casmierone |
1,1,2,3,3-pentamethyl-2,3,6,7-tetrahydro-1h-inden-4(5h)-one |
CHEMBL3183584 |
6,7-dihydro-1,1,2,3,3-pentamethyl-4(5h)-indanone, aldrichcpr |
dpmi 10 microg/ml in cyclohexane |
J-019301 |
CS-0210538 |
mfcd00216987 |
AS-16133 |
1,1,2,3,3-pentamethyl-2,3,4,5,6,7-hexahydro-1h-inden-4-one |
Q1047397 |
1,1,2,3,3-pentamethyl-2,3,4,5,6,7-hexahydroinden-4-one |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 3.4081 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 0.0039 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 48.5577 | 0.0002 | 29.3054 | 16,493.5996 | AID743079 |
activating transcription factor 6 | Homo sapiens (human) | Potency | 0.4897 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (11.11) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 6 (66.67) | 24.3611 |
2020's | 1 (11.11) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.67) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |